Posts Tagged ‘RNAi’
Cequent Pharmaceuticals, a Cambridge, Mass., developer of drugs based on a new gene-silencing technology, raised $9 million in a first-round funding. The round was led by the Novartis Option Fund, joined by Ampersand Ventures, Nexus Medical Partners, and Pappas Ventures.
Cequent is developing new treatments based on RNA interference, a Nobel Prize-winning technology that “silences” gene outputs using short stretches of RNA. Its first candidates, none of which have been tested in humans, are aimed at colon-cancer prevention and inflammatory bowel disease.
Top Stories
- The revenge of the $9.99 iPhone apps
- Fast-growing mobile social network mig33 adds themes, ...
- Report: Facebook not in trouble, still planning ...
- California to set up a $1B electric ...
- Sonic Solutions buys digital video distributor CinemaNow
Recent Guest Columnists
- Javier Rojas
The art of the bootstrap - Clifford Reid
The genomic frontier: Personalized medicine in action - Bruce Cleveland
Double down? Spin in? New questions for a new economy
Job Board
- Regional Vice President of Sales
at Marketing Technology Solutions (Jersey City, NJ) - Interactive Production Designer
at EyeWonder, Inc (233 Peachtree Street Atlanta, GA 30303) - Alliance Marketing Consultant BP
at Sun Microsystems (MENLO PARK, CA) - More Jobs » | Post a Job »
Links
Venturebeat Writers
- Matt Marshall, Editor-in-Chief
- Dean Takahashi, Lead Writer, DigitalMedia
- Eric Eldon, Editor, DigitalMedia
- MG Siegler, Writer, DigitalMedia
- Anthony Ha, Writer, VentureBeat
- Chris Morrison, Writer, CleanTech
- For advertising, contact .
- Log in
Font Size
© 2004-2008(c) Matt Marshall. All rights reserved.Site produced by RubyRed Labs, Evan Levelle
powered by Wordpress